Ana Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Han has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Matthieu Schapira
Structural Genomics Consortium
2 shared publications - Setayesh Yazdani
Structural Genomics Consortium, University of Toronto, MaRS South Tower, Suite 700, 101 College Street, Toronto, ON, M5G 1L7, Canada
2 shared publications - Jiayan Wang
University of Toronto
1 shared publication - Jiayan Wang
Structural Genomics Consortium, University of Toronto, MaRS South Tower, Suite 700, 101 College Street, Toronto, ON, M5G 1L7, Canada
1 shared publication
Latest Publications
- 1 March 2020
- Published by Elsevier in Drug Discovery Today
- Vol. 25 (3) , 561-567
Structure-based view of the druggable genome
- 1 March 2020
- Published by Elsevier in Drug Discovery Today
- Vol. 25 (3) , 561-567
Structure-based view of the druggable genome
- Open Access
- 7 February 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
The Druggable Genome as Seen from the Protein Data Bank
Almost twenty years after the human genome was sequenced, the wealth of data produced by the international human genome project has not translated into a significantly improved drug discovery enterprise. This is in part because small molecule modulators that could be used to explore the cellular function of their target proteins and to discover new therapeutic opportunities are only available for a limited portion of the human proteome. International efforts are underway to develop such chemical tools for a few, specific protein families, and a “Target 2035” call to enable, expand and federate these efforts towards a comprehensive chemical coverage of the druggable genome was recently announced. But what is the druggable genome? Here, we systematically review structures of human proteins bound to drug-like ligands available from the protein databank (PDB) and use ligand desolvation upon binding as a druggability metric to draw a landscape of the human druggable genome. We show that the vast majority of druggable protein families, including some highly populated and deeply associated with cancer according to genomic screens, are almost orphan of small molecule ligands, and propose a list of 46 druggable domains representing 3440 human proteins that could be the focus of large chemical probe discovery efforts.
- 7 February 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Open AccessThe Druggable Genome as Seen from the Protein Data Bank
Almost twenty years after the human genome was sequenced, the wealth of data produced by the international human genome project has not translated into a significantly improved drug discovery enterprise. This is in part because small molecule modulators that could be used to explore the cellular function of their target proteins and to discover new therapeutic opportunities are only available for a limited portion of the human proteome. International efforts are underway to develop such chemical tools for a few, specific protein families, and a “Target 2035” call to enable, expand and federate these efforts towards a comprehensive chemical coverage of the druggable genome was recently announced. But what is the druggable genome? Here, we systematically review structures of human proteins bound to drug-like ligands available from the protein databank (PDB) and use ligand desolvation upon binding as a druggability metric to draw a landscape of the human druggable genome. We show that the vast majority of druggable protein families, including some highly populated and deeply associated with cancer according to genomic screens, are almost orphan of small molecule ligands, and propose a list of 46 druggable domains representing 3440 human proteins that could be the focus of large chemical probe discovery efforts.